All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 163 points (-0.9%) at 17,539 as of Thursday, Nov. 12, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 691 issues advancing vs. 2,260 declining with 136 unchanged.

The Health Care sector currently sits down 0.8% versus the S&P 500, which is down 0.7%. Top gainers within the sector include Intercept Pharmaceuticals ( ICPT), up 5.2%, AbbVie ( ABBV), up 0.7%, Anthem ( ANTM), up 0.6% and Biogen ( BIIB), up 0.5%. On the negative front, top decliners within the sector include Valeant Pharmaceuticals International ( VRX), down 3.7%, Sanofi ( SNY), down 3.0%, Shire ( SHPG), down 2.4%, AstraZeneca ( AZN), down 2.4% and Biomarin Pharmaceutical ( BMRN), down 2.0%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Cigna ( CI) is one of the companies pushing the Health Care sector higher today. As of noon trading, Cigna is up $1.03 (0.8%) to $132.84 on light volume. Thus far, 474,415 shares of Cigna exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $130.73-$133.57 after having opened the day at $131.16 as compared to the previous trading day's close of $131.81.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $34.6 billion and is part of the health services industry. Shares are up 28.1% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts who rate Cigna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and good cash flow from operations. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Cigna Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Illumina ( ILMN) is up $2.75 (1.8%) to $157.72 on light volume. Thus far, 411,838 shares of Illumina exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $153.20-$158.67 after having opened the day at $154.50 as compared to the previous trading day's close of $154.97.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $22.4 billion and is part of the drugs industry. Shares are down 16.0% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts who rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Illumina Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.35 (0.5%) to $64.59 on light volume. Thus far, 1.3 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.7 million shares. The stock has ranged in price between $64.00-$64.67 after having opened the day at $64.05 as compared to the previous trading day's close of $64.24.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $108.5 billion and is part of the drugs industry. Shares are up 8.8% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Bristol-Myers Squibb Company a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).